2023 IDF | Hansoh Pharma Release the Phase 1 Study Data of t a Dual GIP and GLP-1 Receptor Agonist
The IDF Virtual Congress 2023 will be held from December 4 to 7. Phase 1 study data from Hansoh Pharma’s HS-20094 (a novel dual GIP and GLP-1 receptor agonist) will be released at the Congress in the form of posters and oral presentations. This study shows that HS-20094 exhibites good safety, well tolerance, and a good effect in reducing glucose and body weight in healthy adults.